Vaccinex, Inc., a clinical-stage biotechnology company pioneering a differentiated approach to treating Alzheimer’s disease (AD) through the inhibition of Semaphorin 4D (SEMA4D), today announced that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results